HCW Biologics Q1 revenue surges on licensing deal

Hcw Biologics

14/05/2026 21:34

Overview

US biopharma firm's Q1 revenue rose sharply, driven by Trimmune licensing deal closing

Company reported Q1 net income of $3.5 mln, reversing a year-ago loss

Management says substantial doubt exists about ability to continue as going concern

Outlook

Company expects preliminary Phase 1 data for HCW9302 in alopecia areata in H1 2026

Full Phase 1 data for HCW9302 expected in Q4 2026

Company says substantial doubt exists about ability to continue as a going concern without new funding

Result Drivers

TRIMMUNE LICENSE DEAL - Q1 revenue increase attributed to upfront license fee and equity interest from exclusive worldwide licensing agreement with Beijing Trimmune Biotech

LOWER OPERATING EXPENSES - Decreases in R&D and G&A expenses contributed to improved profitability

Company press release: ID:nGNX8x68Hw

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Basic EPS
$0.37


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for HCW Biologics Inc is $2.00, about 472.4% above its May 13 closing price of $0.35

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)